{
  "response": {
    "text": "The clinical trial NCT02294461 was a study evaluating the safety and efficacy of **enzalutamide** in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer (mCRPC) who had disease progression despite androgen deprivation therapy (ADT). Enzalutamide was compared to a placebo.\n\nTherefore, the ingredient starting with the letter \"E\" from this clinical trial is **enzalutamide**.\n\nRegarding the FDA approval for enzalutamide, the drug is marketed under the brand name Xtandy. The initial FDA approval for Xtandy (enzalutamide) was on August 31, 2012, and the company associated with this approval is Astellas Pharma US, Inc. There have been subsequent approvals for new indications and formulations, but the initial overall FDA drug approval for enzalutamide was in 2012.\n\nTherefore, based on the information available:\nCOMPANY: Astellas Pharma US, Inc.",
    "citations": []
  }
}